Trulicity and Imaging Contrast Dye: What You Need to Know Before Your Scan

The Short Answer: Is There a Real Interaction?

There is no direct pharmacokinetic reaction between dulaglutide and iodinated CT contrast agents or gadolinium-based MRI contrast agents. Dulaglutide does not bind to, precipitate with, or alter the metabolism of contrast media in any clinically documented way.

The concern that imaging teams and anesthesiologists have raised is indirect. Dulaglutide, like all GLP-1 receptor agonists, slows gastric emptying. Gastric emptying studies show GLP-1 agonists can reduce the rate of solid-meal emptying by 15 to 30 percent compared to placebo. When your stomach empties more slowly, retained gastric contents can become a problem during procedures that require you to lie flat, receive sedation, or undergo general anesthesia, because the risk of aspiration rises.

That is the interaction. Not a chemical one. A physiological one rooted in how this drug changes your gut.

Why This Matters More for Women

Women already have measurably slower gastric emptying than men at baseline, independent of any medication. A large motility study published in the American Journal of Gastroenterology confirmed that healthy women empty solid meals roughly 20 to 30 minutes more slowly than age-matched men. Layer dulaglutide on top of that, and the stomach may be even slower to clear.

Women with PCOS are disproportionately represented among GLP-1 users, and PCOS itself is associated with elevated insulin and altered gut motility. Women in perimenopause prescribed GLP-1s for metabolic weight management form another large group. Both populations deserve a specific conversation about imaging fasting protocols that accounts for this sex-based difference in baseline gastric physiology.

What Type of Scan Are You Having?

The answer to "how worried should I be" depends heavily on the type of imaging.

• Routine CT with contrast, fully awake, no sedation. Low concern. You will be asked to drink oral contrast or receive IV contrast, but aspiration risk is minimal when you are alert and upright. Standard pre-contrast fasting instructions (typically 4 to 6 hours for solids) may still need to be extended given GLP-1 pharmacology.
• CT enterography or small bowel follow-through. Moderate concern. Delayed gastric emptying can affect how oral contrast moves through your GI tract, potentially making images harder to interpret.
• Sedated or anesthesia-assisted imaging (e.g., MRI requiring deep sedation, CT under conscious sedation). Higher concern. This is the scenario most directly addressed by recent anesthesiology guidance.
• Cardiac CT angiography or nuclear medicine stress testing. Discuss with your cardiologist. Fasting is required and GLP-1 status should be disclosed.

How Dulaglutide Slows Your Stomach: The Physiology Behind the Risk

Dulaglutide works by binding to GLP-1 receptors on pancreatic beta cells to increase insulin secretion, and by acting on the vagus nerve and enteric nervous system to slow how quickly food moves from your stomach into your small intestine. This gastroparesis-like effect is dose-dependent and is measurably present even at the 0.75 mg starting dose, with the 1.5 mg maintenance dose producing more pronounced slowing.

For most people most of the time, this is a feature, not a bug. Slower gastric emptying contributes to the feeling of fullness that makes GLP-1s effective for weight management. The AWARD-11 trial, which studied dulaglutide at doses up to 4.5 mg weekly in people with type 2 diabetes, documented GI side effects including nausea and vomiting in approximately 30 to 40 percent of participants at higher doses, reflecting how significantly this drug moves the needle on gastric motility.

The Aspiration Risk During Imaging

When you receive sedation or general anesthesia for an imaging procedure, your protective airway reflexes are blunted. If your stomach still contains food or liquid because dulaglutide has slowed emptying, you face an elevated risk of pulmonary aspiration. Aspiration pneumonitis is a serious complication.

The American Society of Anesthesiologists issued a 2023 practice advisory specifically addressing GLP-1 agonists before procedures requiring sedation or general anesthesia. The advisory recommends:

• If you take a weekly GLP-1 agonist like dulaglutide and your procedure requires sedation, consider holding the dose on the day of the procedure.
• For procedures scheduled within the usual injection window (i.e., the day your weekly dose would normally be due), discuss with your prescriber whether to skip that week's dose.
• If you have GI symptoms suggesting significant delayed gastric emptying (nausea, vomiting, feeling of fullness hours after meals), a point-of-care gastric ultrasound before sedation may be warranted.

A practical decision framework for women on Trulicity facing imaging:

| Imaging type | Sedation involved? | GLP-1 consideration | |---|---|---| | CT with IV contrast only, awake | No | Disclose GLP-1 use; standard extended fast | | CT enterography, awake | No | Disclose; emptying delay may affect image quality | | MRI without sedation | No | Disclose; no aspiration risk, standard fast | | MRI with sedation/GA | Yes | Discuss holding weekly dose; gastric US if symptomatic | | Nuclear stress test, awake | No | Disclose; follow nuclear medicine fasting protocol | | Fluoroscopy/upper GI series | No | Disclose; motility data may be altered |

Iodinated Contrast and Kidneys: A Separate but Linked Concern

When you receive iodinated contrast for a CT scan, your kidneys filter it out. Contrast-induced nephropathy (now more accurately called contrast-associated acute kidney injury) is a known risk in patients with pre-existing reduced kidney function.

Why does this matter for Trulicity users specifically? Many of the women prescribed dulaglutide have type 2 diabetes or obesity-related metabolic syndrome, conditions that can affect kidney function over time. Dulaglutide itself has a favorable renal profile and is actually studied as a kidney-protective agent. The AWARD-7 trial demonstrated that dulaglutide 1.5 mg weekly preserved estimated glomerular filtration rate (eGFR) better than insulin glargine over 52 weeks in patients with type 2 diabetes and moderate-to-severe chronic kidney disease.

But dulaglutide's renal benefits do not eliminate the need to check your kidney function before receiving iodinated contrast. Your imaging center will check a serum creatinine and eGFR before proceeding with contrast if you have diabetes, hypertension, or any known kidney history. This is standard care regardless of which medications you take.

Gadolinium-Based Contrast (MRI)

Gadolinium contrast agents used in MRI are processed differently than iodinated agents. There is no documented interaction between dulaglutide and any gadolinium-based contrast agent. The main gadolinium concern is nephrogenic systemic fibrosis in patients with severely reduced kidney function (eGFR <30 mL/min/1.73m²), which is assessed independently of GLP-1 use.

What to Tell Your Imaging Team

Walk into any imaging appointment with these facts ready:

1. "I take dulaglutide (Trulicity) once weekly. My last dose was on [date]."
2. "I have [any GI symptoms you've noticed, especially nausea, early satiety, or vomiting]."
3. "My diabetes/metabolic care provider is [name]."

The imaging team should document your GLP-1 use, review your renal function if contrast is planned, and loop in the anesthesiologist or sedation nurse if any sedation is on the schedule.

If your imaging requires sedation and your weekly Trulicity dose is due within 24 to 48 hours of the appointment, contact your prescriber before skipping it independently. Stopping dulaglutide without guidance carries glycemic risk for women with type 2 diabetes.

Pregnancy, Lactation, and Contraception: Required Reading If You Are in Your Reproductive Years

Dulaglutide is contraindicated in pregnancy. This is a hard stop.

Animal reproductive studies showed fetal harm at doses producing exposures below the human therapeutic range. The FDA label for dulaglutide (Trulicity) states that animal studies at doses 0.4 times the maximum recommended human dose caused decreased fetal growth, and advises discontinuing dulaglutide at least 2 months before a planned pregnancy because of the drug's prolonged washout time.

Human data in pregnancy are very limited. Given the two-month washout window recommended before conception attempts, any woman of reproductive age taking dulaglutide should be using reliable contraception if she is not trying to conceive.

The Contrast Dye Issue in Pregnancy

If you are pregnant and need imaging with contrast:

• Iodinated CT contrast. The American College of Radiology states that iodinated contrast can be given during pregnancy when the clinical benefit clearly outweighs the theoretical fetal risk, noting the theoretical concern of transient neonatal hypothyroidism. Neonatal thyroid function should be checked in the first week after birth if a pregnant woman received iodinated contrast.
• Gadolinium MRI contrast. Use in pregnancy is more restricted. The ACR advises gadolinium-based agents should be avoided during pregnancy unless benefit clearly outweighs risk, citing animal data showing fetal harm at high doses.
• Because you should not be on Trulicity during pregnancy, the combined scenario of "pregnant, on Trulicity, needing contrast" should not occur. If you are pregnant and were recently on Trulicity, inform your obstetric team and your radiologist of the timing.

Lactation

There are no data on dulaglutide transfer into human breast milk. The molecular weight of dulaglutide is approximately 63,000 daltons, which makes significant transfer into milk unlikely based on size alone, though this is not confirmed in clinical studies. The FDA label notes the lack of human lactation data and states that a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. This is an honest evidence gap: lactating women have been excluded from GLP-1 trials entirely, and no published pharmacokinetic data in breast milk exist.

Life-Stage Considerations: Who Takes Trulicity and Why It Matters for Imaging

Reproductive-Age Women with PCOS or Type 2 Diabetes

This is the most common group of women on dulaglutide who will also be scheduled for pelvic imaging, abdominal CT, or sometimes CT urography if kidney involvement is suspected. Women with PCOS have a prevalence of type 2 diabetes roughly 3 to 7 times higher than age-matched women without PCOS, making GLP-1 use very relevant in this cohort. Pelvic MRI without sedation is generally low risk from a GLP-1 standpoint; the gastroparesis conversation becomes urgent only if sedation is added.

Perimenopausal and Postmenopausal Women

Perimenopausal women are the fastest-growing group being prescribed GLP-1 agonists for menopausal weight gain and metabolic syndrome. They are also the group most likely to need cardiac CT angiography, bone density scanning with contrast-enhanced MRI, or other imaging as screening tools. Estrogen decline in perimenopause is independently associated with slowed gut motility, meaning the additive effect with dulaglutide may be most pronounced in this life stage.

A 2022 review in Menopause confirmed that gastrointestinal motility slows significantly during the menopausal transition, driven in part by falling estrogen and progesterone. A perimenopausal woman on 1.5 mg dulaglutide weekly may have substantially delayed gastric emptying before any imaging appointment, and the extended fasting protocol becomes more important to emphasize in this group.

Women Being Evaluated for Obesity-Related Conditions

Dulaglutide at 1.5 mg is approved for type 2 diabetes management. Off-label or trial-stage use for weight management in women without diabetes is ongoing. Women seeking bariatric evaluation or weight-management programs commonly undergo imaging. Abdominal CT to assess hepatic steatosis, liver size before surgery, or adrenal imaging when evaluating secondary causes of weight gain all require the imaging team to know about GLP-1 use.

"Can I Drink Alcohol on Trulicity?" and the Imaging Day Question

Alcohol is worth addressing here because it intersects with both Trulicity pharmacology and imaging preparation.

Alcohol and dulaglutide do not have a direct pharmacological interaction. Alcohol does not alter dulaglutide's absorption (which is subcutaneous), its receptor binding, or its GLP-1-mediated effects in any documented way.

The indirect concerns are:

• Alcohol can cause hypoglycemia in women with type 2 diabetes, especially when combined with medications that stimulate insulin secretion (dulaglutide itself has a glucose-dependent mechanism and carries low standalone hypoglycemia risk, but the combination with alcohol warrants caution).
• On the day before or day of imaging that requires contrast, alcohol can contribute to dehydration, which modestly elevates the risk of contrast-associated kidney injury.
• If sedation is planned, alcohol in the preceding 24 hours is independently contraindicated.

The practical answer: an occasional drink is not contraindicated on dulaglutide, but imaging day and the night before are not the times to test that.

What About Drug Interactions More Broadly on Trulicity?

Dulaglutide's most documented drug interaction category is the delayed absorption of orally administered medications caused by slowed gastric emptying. The Trulicity prescribing information notes that dulaglutide slows gastric emptying and may influence the absorption of concomitantly administered oral medications. Drugs with narrow therapeutic windows that rely on predictable oral absorption deserve attention.

For imaging specifically:

• Oral contrast agents taken before CT: delayed gastric emptying means they may not clear the stomach or move through the bowel at expected rates. Radiologists should be aware when interpreting bowel-opacification quality.
• Oral premedication for contrast allergy (e.g., prednisone taken the night before and morning of): absorption may be mildly delayed but not clinically significant for a premedication protocol.
• Metformin: this is a separate but important note. Many women on dulaglutide are also on metformin. ACOG and the FDA recommend withholding metformin before iodinated contrast administration in patients at risk for contrast-induced nephropathy, specifically those with eGFR <60 mL/min/1.73m², and resuming only after renal function is confirmed stable 48 hours later. The imaging team will address metformin separately, but you should mention both medications.

The Evidence Gap: What We Do Not Yet Know

Women have been significantly underrepresented in GLP-1 pharmacokinetic and imaging preparation trials. A 2020 analysis in JAMA Network Open found that women make up a minority of participants in metabolic drug trials despite being disproportionately affected by conditions like PCOS and obesity-related type 2 diabetes. Virtually all of the gastric emptying data we have on GLP-1 agonists comes from trials that either did not stratify by sex or enrolled predominantly male participants.

What we do not know:

• Whether sex-specific differences in baseline gastric emptying velocity compound the GLP-1 effect enough to require systematically different fasting times for women.
• Whether menstrual cycle phase (gastric emptying is measurably faster in the follicular phase than the luteal phase) interacts with GLP-1-slowed motility to affect imaging day aspiration risk.
• Lactation pharmacokinetics for any GLP-1 agonist.

These are not minor gaps. Until sex-stratified data exist, clinical teams should err toward the more conservative fasting and precaution protocols when managing women on dulaglutide before imaging.

Who This Is and Is Not Right For

Continuing Trulicity through a routine imaging appointment is appropriate if:

• You are having awake, unsedated imaging (CT, MRI, X-ray, ultrasound).
• You have no symptoms of significant gastroparesis (no persistent nausea, vomiting, or early satiety).
• Your kidney function is stable and has been checked within the past year.
• You have told the imaging team you take a weekly GLP-1 agonist.

A conversation with your prescriber before imaging is warranted if:

• Sedation or general anesthesia is part of the imaging procedure.
• You have active GI symptoms suggesting delayed gastric emptying.
• You are having CT enterography where motility assessment is part of the clinical question.
• You have eGFR <60 mL/min/1.73m² and will receive iodinated contrast.
• You are in your reproductive years without reliable contraception (address the pregnancy question before any elective imaging that involves radiation or contrast).

Dulaglutide must be stopped before:

• Planned pregnancy (minimum 2 months before attempting conception per the FDA label).
• Any imaging in pregnancy (address contraception adequacy at every visit).